一氧化碳弥散量在慢阻肺评估中的作用
基于COPDGene研究5年随访的1,806例慢阻肺患者,分析Dlco与症状、生活质量、运动能力和急性加重的关系。多变量分析显示,Dlco每降低10%预计值与症状加重、生活质量下降、运动能力减低及重度急性加重风险增加独立相关,即使校正肺功能和CT肺气肿后仍显著。
要点
- Dlco降低与慢阻肺症状、生活质量和运动能力下降独立相关。
- Dlco每降低10%预计值,重度急性加重风险增加14%。
- 即使校正FEV1和CT肺气肿,Dlco仍与不良结局相关。
核心结论
- Dlco受损与慢阻肺症状增多、运动能力下降和重度急性加重风险增加相关,且独立于肺功能和CT肺气肿。
- 建议未来慢阻肺多维评估工具纳入Dlco。
研究设计与样本
- COPDGene研究5年随访的1,806例慢阻肺 participant 数据分析。
- 纳入肺功能、生活质量、症状、运动能力和急性加重率。
- 采用多变量线性和负二项回归模型,校正肺气肿和FEV1%预计值等混杂因素。
主要发现
- Dlco每降低10%预计值,CAT评分增加0.53(P < .001)。
- Dlco每降低10%预计值,SGRQ评分增加1.67(P < .001)。
- Dlco每降低10%预计值,SF-36生理功能评分降低0.89(P < .001)。
- Dlco每降低10%预计值,6分钟步行距离减少45.35英尺(P < .001)。
- Dlco每降低10%预计值,重度急性加重率比为1.14(P < .001)。
关键数值与推荐
- Dlco分组:Dlco和FEV1均>50%预计值(参照组);仅Dlco≤50%;仅FEV1≤50%;两者均≤50%。
- 与参照组相比,仅Dlco≤50%、仅FEV1≤50%或两者均≤50%均与更差的发病率显著相关(所有结局P < .05)。
临床怎么用
- 在慢阻肺评估中应考虑检测Dlco,以识别即使FEV1保留但Dlco受损的高危患者。
- Dlco下降可提示症状负担、运动能力下降和急性加重风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffusing capacity of the lung for carbon monoxide (Dlco) is inconsistently obtained in patients with COPD, and the added benefit of Dlco testing beyond that of more common tools is unknown. OBJECTIVE: The goal of this study was to determine whether lower Dlco is associated with increased COPD morbidity independent of emphysema assessed via spirometry and CT imaging. METHODS: Data for 1,806 participants with COPD from the Genetic Epidemiology of COPD (COPDGene) study 5-year visit were analyzed, including pulmonary function testing, quality of life, symptoms, exercise performance, and exacerbation rates. Dlco percent predicted was primarily analyzed as a continuous variable and additionally categorized into four groups: (1) Dlco and FEV1 > 50% (reference); (2) only Dlco ≤ 50%; (3) only FEV1 ≤ 50%; and (4) both ≤ 50% predicted. Outcomes were modeled by using multivariable linear and negative binomial regression, including emphysema and FEV1 percent predicted among other confounders. RESULTS: In multivariable analyses, every 10% predicted decrease in Dlco was associated with symptoms and quality of life (COPD Assessment Test, 0.53 [P < .001]; St. George's Respiratory Questionnaire, 1.67 [P < .001]; Medical Outcomes Study Short Form 36 Physical Function, -0.89 [P < .001]), exercise performance (6-min walk distance, -45.35 feet; P < .001), and severe exacerbation rate (rate ratio, 1.14; P < .001). When categorized, severe impairment in Dlco alone, FEV1 alone, or both Dlco and FEV1 were associated with significantly worse morbidity compared with the reference group (P < .05 for all outcomes). CONCLUSIONS: Impairment in Dlco was associated with increased COPD symptoms, reduced exercise performance, and severe exacerbation risk even after accounting for spirometry and CT evidence of emphysema. These findings suggest that Dlco should be considered for inclusion in future multidimensional tools assessing COPD.
引用
- Balasubramanian A, MacIntyre NR, Henderson RJ, et al. Diffusing Capacity of Carbon Monoxide in Assessment of COPD. Chest. 2019. PMID: 31352035. doi:10.1016/j.chest.2019.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。